Evidence map›Paper›PMID 40600960›Full record

ArticleMolecular pharmaceutics2025

Magnetic Nanoworm-Based Screening of Yeast Library for Anti-PEG Nanobodies.

Shashikant Ray, Sarah Jacques, Utibeabasi Ettah, Shaodong Dai, Hanmant K Gaikwad, Robert I Scheinman, Krishna M G Mallela, Dmitri Simberg

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shashikant RayDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States.
Sarah JacquesDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States.
Utibeabasi EttahDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States.
Shaodong DaiDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States.
Hanmant K GaikwadDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States.ORCID 0000-0001-5526-0545
Robert I ScheinmanDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States.
Krishna M G MallelaDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States.ORCID 0000-0001-8308-5318
Dmitri SimbergDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States.ORCID 0000-0002-5288-6275

Funding

The Alternative Complement Pathway and Hemocompatibility of NanosurfacesR01AI154959 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Dmitri Simberg · 2020 to 2026
$3.5M
Fluorescent Indocarbocyanine PEGylated Lipid Nanoparticles for Understanding and Overcoming Barriers to Drug Delivery in Invasive GlioblastomaR01CA257958 · NCI · UNIVERSITY OF COLORADO DENVER · PI Irina V Balyasnikova, Dmitri Simberg · 2022 to 2026
$2.7M
Characterization of disulfide modified diabetogenic neoepitopesR01DK137056 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI SHAODONG DAI · 2023 to 2026
$1.8M
NCI NIH HHS R01 CA257958NIAID NIH HHS R01 AI154959NIDDK NIH HHS R01 DK137056
6 · The paper itself

Abstract

PEGylation is commonly utilized to modify nanoparticles, vaccines, therapeutic proteins, and biomaterials. The increased use of PEG-containing cosmetics and medicines results in anti-PEG immunoglobulins in humans, including IgG, IgM, and IgE types. Recent studies have shown that high-affinity antibodies against PEG can be isolated through immunization. These antibodies have been used in immunoassays and for decorating PEGylated nanoparticles with targeting ligands. However, conventional antibodies have limitations, such as their large size and potential stability issues. Here, we developed a protocol to isolate anti-PEG nanobodies (Nbs) from a yeast library. We prepared ∼60 nm fluorescently labeled PEGylated and non-PEGylated iron oxide nanoworms for negative and positive magnetic selection, followed by multiparameter flow cytometry sorting. The representative Nb clone exhibited highly specific binding to PEGylated liposomes and nanoparticles and was able to compete with commercial antibackbone PEG IgG but not with anti-methoxy PEG IgG for PEG binding. The Nb showed a micromolar dissociation constant, no aggregation, high thermal stability, and reversible structural stability. This work represents a proof-of-concept screening and isolation of anti-PEG Nbs.

Indexed as

Polyethylene GlycolsSaccharomyces cerevisiaeSingle-Domain AntibodiesFerric CompoundsFlow CytometryHumansImmunoglobulin GLiposomesNanoparticlesFerric Compoundsferric oxideImmunoglobulin GLiposomesPolyethylene GlycolsSingle-Domain AntibodiesaffinitynanobodynanoparticlePEGthermal stabilityyeast display

Identifiers

PMID40600960
PMCPMC13251789

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.